Specialty biologic drug coverage under Medicare Part D: The experience of beneficiaries with rheumatoid arthritis (RA) and multiple sclerosis (MS)

被引：0
|
作者：
Polinski, Jennifer M. [1 ,3 ]
Mohr, Penny E. [2 ]
Johnson, Lorraine [2 ]
机构：
[1] Brigham & Womens Hosp, Div Pharmaocoepidemiol & Pharmacoecon, Boston, MA 02115 USA
[2] CMS, Off Res Dev & Informat, Baltimore, MD USA
[3] Harvard Univ, Sch Med, Boston, MA USA
来源：
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY | 2008年 / 17卷
关键词：
D O I：
暂无
中图分类号：
R1 [预防医学、卫生学];
学科分类号：
1004 ; 120402 ;
摘要：
068
引用
收藏
页码：S30 / S30
页数：1
相关论文
共 32 条
  • [1] Specialty biologic drug coverage under medicare Part D: The experience of vulnerable beneficiaries with rheumatoid arthritis (RA) and multiple sclerosis (MS)
    Polinski, J. M.
    Mohr, P. E.
    Johnson, L.
    [J]. VALUE IN HEALTH, 2008, 11 (03) : A35 - A35
  • [2] IMPACT OF COST SHARING INCREASES UNDER PART D SPECIALTY TIERS ON BIOLOGIC ADHERENCE AND DISCONTINUATION AMONG MEDICARE BENEFICIARIES WITH MULTIPLE SCLEROSIS OR RHEUMATOID ARTHRITIS
    Li, P.
    Hu, T.
    Yu, X.
    Chahin, S.
    Dahodwala, N. A.
    Doshi, J. A.
    [J]. VALUE IN HEALTH, 2015, 18 (03) : A79 - A80
  • [3] Predictors of medicare part D enrollment: the experience of Medicare drug demonstration participants with rheumatoid arthritis (RA) and multiple sclerosis
    Polinski, Jennifer M.
    Mohr, Penn E.
    Johnson, Lorraine
    [J]. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2008, 17 : S206 - S207
  • [4] Impact of Medicare Part D on Access to and Cost Sharing for Specialty Biologic Medications for Beneficiaries With Rheumatoid Arthritis
    Polinski, Jennifer M.
    Mohr, Penny E.
    Johnson, Lorraine
    [J]. ARTHRITIS & RHEUMATISM-ARTHRITIS CARE & RESEARCH, 2009, 61 (06): : 745 - 754
  • [5] Predictors of enrollment in medicare Part D: The experience of medicare drug demonstration participants with rheumatoid arthritis and multiple sclerosis
    Polinski, J. M.
    Mohr, P. E.
    Johnson, L.
    [J]. VALUE IN HEALTH, 2008, 11 (03) : A34 - A35
  • [6] Specialty Tier-Level Cost Sharing and Biologic Agent Use in the Medicare Part D Initial Coverage Period Among Beneficiaries With Rheumatoid Arthritis
    Doshi, Jalpa A.
    Hu, Tianyan
    Li, Pengxiang
    Pettit, Amy R.
    Yu, Xinyan
    Blum, Marissa
    [J]. ARTHRITIS CARE & RESEARCH, 2016, 68 (11) : 1624 - 1630
  • [7] Coverage for High-Cost Specialty Drugs for Rheumatoid Arthritis in Medicare Part D
    Yazdany, Jinoos
    Dudley, R. Adams
    Chen, Randi
    Lin, Grace A.
    Tseng, Chien-Wen
    [J]. ARTHRITIS & RHEUMATOLOGY, 2015, 67 (06) : 1474 - 1480
  • [8] Adequacy Of Drug Coverage and Cost-Sharing For Medicare Beneficiaries With Rheumatoid Arthritis
    Yazdany, Jinoos
    Dudley, R. Adams
    Chen, Randi
    Tseng, Chien-Wen
    [J]. ARTHRITIS AND RHEUMATISM, 2013, 65 : S426 - S426
  • [9] Health care utilization by medicare advantage beneficiaries in the era of the medicare part D drug benefit coverage gap
    Delate, T.
    Raebel, M. A.
    Ellis, J. L.
    Bayliss, E. A.
    [J]. VALUE IN HEALTH, 2008, 11 (03) : A12 - A12
  • [10] Trends in Coverage for Disease Modifying Therapies for Multiple Sclerosis in Medicare Part D
    Hartung, Daniel
    Johnston, Kirbee
    Bourdette, Dennis
    [J]. NEUROLOGY, 2018, 90
1234